Based on the updated case series repository, here is the specific case data, regimens, and reported outcomes across lymphoma, melanoma, and sarcoma:
1. Lymphoma (25–32 Documented Cases)
Case reports in lymphoma encompass diverse subtypes—including Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin lymphoma, Follicular lymphoma, and Mantle Cell lymphoma—frequently noting rapid radiological clearance or reduction in chemotherapy side effects:
Stage 4 DLBCL (Bone Metastases): A 60-year-old male took IP6, ivermectin (1 mg/kg/day), and fenbendazole (1,776 mg/day). His largest tumor measured 6 cm; he achieved complete remission on PET scan in less than two months.
DLBCL with Chemo Synergy (R-CHOP): A 40-year-old male with 9 cm and 4 cm supraspinatus masses took ivermectin (1 mg/kg/day), fenbendazole (1,500 mg/day), and CBD oil alongside R-CHOP chemotherapy. His oncologist reported the masses disappeared after 3 cycles, achieving a complete metabolic response with no reported chemotherapy side effects.
Stage 4 DLBCL Monotherapy (No Chemo): A 49-year-old male discontinued R-CHOP after cycle 1 due to severe toxicity and weight loss. He started ivermectin (1 mg/kg/day) and fenbendazole (1,332 mg/day); after 3 months, CT imaging revealed an almost complete response, leaving only minimal residual mesenteric nodularity (3×2 cm).
Stage 4a DLBCL (Published Case, 2020): An 83-year-old male declined chemotherapy and self-administered fenbendazole at 1,000 mg daily. After developing peripheral neuropathy, he tapered the dose down to 1–3 tablets daily and eventually 3 tablets weekly. Serial CT and PET/CT scans showed continuous reduction and interval improvement of mediastinal lymphadenopathy with no new lesions.
Stage 3 & 4 Follicular Lymphoma:
An 83-year-old male on “watch and wait” took ivermectin (1 mg/kg/day), fenbendazole (444 mg/day), and melatonin (120 mg/day). At 6 months, PET/CT scans showed dramatic improvement across neck-to-groin lymphadenopathy (largest node shrank from 3.4×1.9 cm to 1.0×0.7 cm; SUVmax dropped from 9.5 to 1.3), with an estimated 99% disease clearance without chemo or radiation.
A 70-year-old male with bone metastases received ivermectin (1 mg/kg/day), fenbendazole (1,000 mg/day), CBD oil, and R-CHOP, achieving a completely clean PET scan by month 3–4, confirmed again at 6 months.
Mantle Cell Lymphoma: A 60-year-old female with progressive disease and bowel involvement took ivermectin (1 mg/kg/day) and fenbendazole (titrated from 888 mg to 1,332 mg/day). Follow-up CT scans at 3.5 months documented 87.5% to 96.3% tumor shrinkage across neck, mediastinal, axillary, and abdominal lymph nodes.
Hodgkin Lymphoma:
A 46-year-old male with an 11 cm anterior mediastinal mass took ivermectin (1–2 mg/kg/day), fenbendazole (1,332 mg/day), CBD, and melatonin with radiation; the tumor shrank to 2.9 cm with zero FDG uptake (metabolic remission).
A 36-year-old male took “triple therapy” (ivermectin 1.5 mg/kg/day, fenbendazole 1,500 mg/day, mebendazole 1,500 mg/day) and noted a complete absence of expected side effects during his chemotherapy cycle.
2. Melanoma & Skin Cancers (13–16 Documented Cases)
Reported melanoma cases frequently involve advanced Stage 4 disease with widespread visceral and CNS metastases, with several accounts highlighting combination protocols with modern checkpoint inhibitors:


